The Influenza A Virus, H1N1 Subtype Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Influenza A Virus, H1N1 Subtype Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued products.
GlobalData tracks 96 drugs in development for Influenza A Virus, H1N1 Subtype Infections by 83 companies/universities/institutes. The top development phase for Influenza A Virus, H1N1 Subtype Infections is preclinical with 44 drugs in that stage. The Influenza A Virus, H1N1 Subtype Infections pipeline has 74 drugs in development by companies and 22 by universities/ institutes. Some of the companies in the Influenza A Virus, H1N1 Subtype Infections pipeline products market are: Moderna, University of Hong Kong and Novavax.
The key targets in the Influenza A Virus, H1N1 Subtype Infections pipeline products market include Hemagglutinin HA, Hemagglutinin, and Neuraminidase.
The key mechanisms of action in the Influenza A Virus, H1N1 Subtype Infections pipeline product include Neuraminidase Inhibitor with four drugs in Preclinical. The Influenza A Virus, H1N1 Subtype Infections pipeline products include ten routes of administration with the top ROA being Intramuscular and 19 key molecule types in the Influenza A Virus, H1N1 Subtype Infections pipeline products market including Subunit Vaccine, and Small Molecule.
Influenza A Virus, H1N1 Subtype Infections overview
H1N1 infection, also known as swine flu, is a new kind of flu in humans caused by a contagious influenza virus strain. H1N1 flu infects the nose, throat, and lungs. It is spread by droplets distributed by coughing or sneezing. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache, and fatigue. Treatment includes medication (antiviral drugs).
For a complete picture of Influenza A Virus, H1N1 Subtype Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
